Form 4: Greenwich LifeSciences VP Acquires 1,000 Shares of Common Stock
SEC Form 4
Jaye Thompson, VP of Clinical and Regulatory Affairs at Greenwich LifeSciences, purchased 1,000 shares of common stock at $15.15 per share on August 2, 2024.
Summary
- On August 2, 2024, Jaye Thompson, VP of Clinical and Regulatory Affairs at Greenwich LifeSciences, acquired 1,000 shares of common stock.
- The purchase price was $15.15 per share.
- Following the transaction, Thompson directly owns 262,348 shares of Greenwich LifeSciences common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The purchase of shares by a company executive is generally viewed as a positive sign, indicating confidence in the company's future. However, the purchase is relatively small.
Positives
- The VP's purchase could be interpreted as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider trading activity is closely monitored by investors as it can provide insights into a company's performance and future prospects. Purchases by executives are often seen as a positive sign.
Stakeholder Impact
- The purchase of shares by a company executive can positively influence shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 08/02/2024 | Date of transaction: Jaye Thompson purchased 1,000 shares of common stock. |
| 08/05/2024 | Date of signature on the SEC Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.